Partners

Our Partners
CEVHAP is grateful for the time and support of our own members, freely given, as well as the representatives of the following partner organisations:

Advocomm Singapore Pte Ltd
www.advocomm-sg.com

American Association for the Study of Liver Diseases
www.aasld.org

Asian Pacific Association for the Study of the Liver (APASL)
www.apasl.info

Australian Research Centre in Sex, Health and Society at La Trobe University
www.latrobe.edu.au

Australasian Society for HIV Medicine
www.ashm.org.au

Centers for Disease Control and Prevention, USA
www.cdc.gov

European Association for the Study of the Liver
www.easl.eu

Fleishman-Hillard, Asia Pacific
www.fleishman.com.hk

Golin Harris (Taiwan)
www.golinharris.com

Hepatitis B Foundation, USA
www.hepb.org

Korean Association for the Study of the Liver
www.kasl.org/english/introduction.htm

Kromite
www.kromite.com

Victorian Infectious Diseases Reference Laboratory (VIDRL)
www.vidrl.org.au

World Hepatitis Alliance (WHA)
www.worldhepatitisalliance.org

Yao Li Wang

www.yaoliwang.com

Donors & Sponsors

CEVHAP has introduced three tiers of funding to recognise the generous support of our donors and sponsors in providing a mixture of untied grants and donations, or sponsorship funding to support specific projects. This funding has been vital in enabling the development of policy research projects, outreach programmes and essential operational support.

Advocomm Singapore Pte Ltd

Bristol-Myers Squibb

Gilead

Janssen

MSD

 

CEVHAP welcomes donations from a broad spectrum of donors including NGOs, governments and commercial organisations who are supportive of CEVHAP’s objectives in working to reduce the burden of viral hepatitis in Asia Pacific.

 

 

 

FaLang translation system by Faboba

 CEVHAP-CUHK Hepatitis Policy in Asia June 2017

>> Viral Hepatitis Asia Survey 2016

 

nohep.logo_horizontal.jpg

NOhep is a global, grassroots movement aimed at bringing all stakeholders together to eliminate viral hepatitis by 2030. It has been developed to create global awareness of the disease, similar to the red ribbon for HIV/AIDS, and was launched in 2016. NOhep firmly positions itself at the forefront of the elimination conversation, showcasing exemplary leadership, fostering on-the-ground innovative solutions and taking action to support the policy changes needed to eliminate this cancer-causing illness by 2030. Being a part of NOhep means being part of the solution. (To find out more about the development of this exciting initiative, watch this short video: https://youtu.be/Oer-rGwnKZU

 

CEVHAP Activity Report Brochure EMAIL smaller Cover

>> FAST FACTS
Viral Hepatitis
  Globally, 2 billion people have been
infected with hepatitis B virus, with an
estimated 600,000 dying each year . . .
  The number of people with chronic
hepatitis C and more advanced liver
disease or cirrhosis, is projected to
increase by 38% between 2006 and 2015
unless the number of people being
treated increases substantially.
  There is no vaccine for hepatitis C but
approximately 80% of patients who are
able to complete recommended
treatment, are cured . . .
World Hepatitis Day
July 28
WHD 2013

One million people die from viral 
hepatitis in Asia Pacific every year.
On WORLD HEPATITIS DAY CEVHAP 
urges governments to embrace WHO's
new global framework for action.
                                >> READ MORE

>> FEATURED VIDEOS 
Why hepatitis policy matters - the story of Baltazar Lucas  
 
Video What are the dangers of viral #hepatitis? Hear what #CEVHAP Chair Prof Ding-Shinn Chen had to say to the Wall Street Journal.
  
A Message from DS Chen
Chairman, CEVHAP

 

Connect with usconnect with CEVHAP